Ganglioside GM3 inhibition of EGF receptor mediated signal transduction

• Published in: Glycobiology (Oxford) 1996-06, Vol.6 (4), p.399-406
• Main Authors: Rebbaa, Abdelhadi, Hurh, Jay, Yamamoto, Hirotaka, Kersey, Donna S., Bremer, Eric G.
• Format: Article
• Language: English
• Subjects: Cell Division - drug effects; Cell Division - physiology; cell growth; Cell Line; epidermal growth factor; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - metabolism; G(M3) Ganglioside - physiology; gangliosides; Gene Expression Regulation - drug effects; Gene Expression Regulation - physiology; Genes, Immediate-Early; GM3; Humans; Isoxazoles - pharmacology; Leflunomide; Signal Transduction
• ISSN: 0959-6658; 1460-2423
• DOI: 10.1093/glycob/6.4.399

Ganglioside GM3 is a membrane component that has been described to modulate cell growth through inhibition of EGF receptor associated tyrosine kinase. In order to determine if the inhibition of cell growth by this ganglioside is specifically mediated through EGF receptor signaling, the effects of GM3 on key enzymes implicated in EGF signaling were determined and compared to another inhibitor of the EGF receptor kinase. Treatment of A1S cells in culture by GM3 or a tyrosine kinase inhibitor, leflunomide, led to the inhibition of MAP kinase and PI3 kinase activities. There was no detectable effect on phosphotyrosine phosphatases. In a cell free system, however, GM3 had no effect on the activity of these signaling intermediates. Leflunomide was able to directly inhibit MAP kinase activity. GM3 and leflunomide were also found to act differently on the expression of the early immediate genes. The expression of c-fos and c-jun was inhibited by both GM3 and leflunomide. The expression of c-myc, however, was only inhibited by leflunomide. These findings suggest that the action of GM3 on cell growth and signaling is specifically mediated by EGF receptor and that this ganglioside does not act directly on the intracellular intermediates of EGF receptor signaling. In addition, soluble small molecule tyrosine kinase inhibitors such as leflunomide can directly affect the activity of MAP kinases and possibly other signaling intermediates. The direct effects of leflunomide on signaling intermediates may explain the differential effects of leflunomide and GM3 on gene expression and cell growth.